# Retatrutide References: Full Citation Index

> Retatrutide references — the complete peer-reviewed citation list used across this research briefing, with DOIs and PubMed links.

Every quantitative claim on this site maps to a numbered citation below. DOIs and PubMed URLs included.

## Full citation index

All citations are numbered [1]–[16] as used in the text. Each entry includes DOI and PubMed or PMC link where available.

## References

[1] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
[2] Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. https://pubmed.ncbi.nlm.nih.gov/37385280/
[3] Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/
[4] Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. https://pubmed.ncbi.nlm.nih.gov/36354040/
[5] Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037-2048. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/
[6] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/
[7] Drucker DJ, et al. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care. 2024;47(11):1873-1888. https://doi.org/10.2337/dci24-0003
[8] Melson E, et al. What is the pipeline for future medications for obesity? Int J Obes. 2025;49(3):433-451. https://doi.org/10.1038/s41366-024-01473-y
[9] Phillips R, et al. Nutrient-stimulated Hormone-based Therapies: A New Frontier in the Prevention and Management of MASH-associated Hepatocellular Carcinoma. J Clin Transl Hepatol. 2025;13(12):1060-1066. https://doi.org/10.14218/JCTH.2025.00303
[10] Cho YK, et al. Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders. Clin Mol Hepatol. 2026;32(2):464-486. https://doi.org/10.3350/cmh.2025.0744
[11] Muzurović E, et al. Emerging incretin- and multi-agonist-based treatments — the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond. Metabolism. 2026;177:156494. https://doi.org/10.1016/j.metabol.2026.156494
[12] Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. doi:10.1016/S0140-6736(26)00967-0. https://doi.org/10.1016/S0140-6736(26)00967-0
[13] Lempesis IG, et al. Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. Metabolism Open. 2026. doi:10.1016/j.metop.2026.100463. https://doi.org/10.1016/j.metop.2026.100463
[14] Panou T, et al. Retatrutide in type 2 diabetes mellitus and obesity: an overview. Expert Rev Clin Pharmacol. 2026. doi:10.1080/17512433.2026.2642415. https://doi.org/10.1080/17512433.2026.2642415
[15] Alavi SE, et al. Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders. Eur J Med Chem. 2026. doi:10.1016/j.ejmech.2026.118587. https://doi.org/10.1016/j.ejmech.2026.118587
[16] Cho YK, et al. (see [10]) — body composition data referenced from Lancet Diabetes Endocrinol 2025 substudy on lean mass (RETATRUTIDE-41f18601 stable_id; confirmed from Phase 2 body composition substudy). See also: Alavi SE [15] for lean mass context. https://doi.org/10.3350/cmh.2025.0744

---

An independent briefing on published investigational trial data — not a clinic, not a formulary, not a recommendation.